Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company's Investigational Treatment for Contact Lens Discomfort
Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company’s Investigational Treatment for Contact Lens Discomfort Significant improvement in multiple measures of Meibomian gland secretion and associated improvements in contact lens wear time TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today a...
Source: ibtimes.com.au